Clinical Trials Logo

Clinical Trial Summary

This is an open label single arm feasibility trial. A combination of two oral agents (pravastatin and lonafarnib) and one intravenous (IV) agent (zoledronic acid) will be administered at doses and schedule currently applied in pediatrics. These agents all target farnesylation pathways at different points. Our goal is to inhibit farnesylation of abnormal lamin, the disease-causing protein in Hutchinson-Gilford Progeria Syndrome and progeroid laminopathies (henceforth "progeria"). The drugs will include the intravenous bisphosphonate zoledronic acid, oral HMG co-reductase inhibitor pravastatin and the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH 66336). Patients with genetically confirmed progeria will be eligible for this protocol. Treatment will be initiated for 4 weeks duration and may be extended depending on tolerability. This study will assess the feasibility of this treatment regimen in the first 4 weeks. If tolerated for 4 weeks, patients can be treated with this regimen for up to 6 months.


Clinical Trial Description

Progerias are rare "premature aging" diseases in which children die of severe atherosclerosis leading to strokes and heart attacks. It is a multisystem disease with objective clinical markers for disease progression. These include abnormalities in growth and body composition, bone mineral density, join function, endocrine function, alopecia, and vascular disease. There is currently no therapy proven effective for any of the progressive and deleterious aspects of this disorder.

Progeria is caused by a gene defect in the gene LMNA, coding for the nuclear protein lamin A. Lamin A is normally expressed by most differentiated cells, and requires posttranslational farnesylation to incorporate into the nuclear membrane. This trial proposes to use three agents (zoledronic acid, pravastatin, and lonafarnib) to inhibit farnesylation of abnormal lamin, the disease causing protein in Progeria. The primary objective of this study is to evaluate the feasibility of administering intravenous zoledronic acid, oral pravastatin and oral lonafarnib, to patients wtih Progeria for a minimum of 4 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00879034
Study type Interventional
Source Boston Children’s Hospital
Contact
Status Completed
Phase Phase 2
Start date March 2009
Completion date April 2009

See also
  Status Clinical Trial Phase
Completed NCT00094393 - Clinical Studies of Progeria
Completed NCT00425607 - Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria Phase 2
Enrolling by invitation NCT02579044 - Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria Phase 1/Phase 2
Active, not recruiting NCT00916747 - Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria Phase 2
Approved for marketing NCT03895528 - Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy